Veronique R. De Jager

Veronique R. De Jager

Auto-generated profile, based on publicly available information

Veronique R. De Jager

TASK Applied Science Clinical Research Center Cape Town South Africa

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
YXYingda L. Xie
Yingda L. Xie
VJVeronique R. de Jager
Veronique R. de Jager
RCRay Y. Chen
Ray Y. Chen
LDLori E. Dodd
Lori E. Dodd
PPPraveen Paripati
Praveen Paripati
CIClifton Earl Barry, III
Clifton Earl Barry, III
Early bactericidal activity studies monitor daily sputum bacterial counts in individuals with tuberculosis (TB) for 14 days during experimental drug treatment. The rate of change in sputum bacterial load over time provides an informative, but imperfect, estimate of drug activity and is considered a critical step in development of new TB drugs. In this clinical study, 160 participants with TB received isoniazid, pyrazinamide, or rifampicin, components of first-line chemotherapy, and moxifloxacin individually and in combination. In addition to standard bacterial enumeration in sputum, participants underwent 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography and computerized tomography ([18F]FDG-PET/CT) at the beginning and end of the 14-day drug treatment. Quantitating radiological responses to drug treatment provided comparative single and combination drug activity measures across lung lesion types that correlated more closely with established clinical outcomes when combined with sputum enumeration compared to sputum enumeration alone. Rifampicin and rifampicin-containing drug combinations were most effective in reducing both lung lesion volume measured by CT imaging and lesion-associated inflammation measured by PET imaging. Moxifloxacin was not superior to rifampicin in any measure by PET/CT imaging, consistent with its performance in recent phase 3 clinical trials. PET/CT imaging revealed synergy between isoniazid and pyrazinamide and demonstrated that the activity of pyrazinamide was limited to lung lesion, showing the highest FDG uptake during the first 2 weeks of drug treatment. [18F]FDG-PET/CT imaging may be useful for measuring the activity of single drugs and drug combinations during evaluation of potential new TB drug regimens before phase 3 trials.

15 May 2022 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
VJVeronique De Jager
Veronique De Jager
NGNikhil Gupte
Nikhil Gupte
SNSilvia Nunes
Silvia Nunes
GBGrace L. Barnes
Grace L. Barnes
Rob van WijkRob van Wijk
Rob van Wijk
KDKelly E Dooley
Kelly E Dooley
Rationale: Carbapenems are recommended for treatment of drug-resistant tuberculosis. Optimal dosing remains uncertain. Objectives: To evaluate the 14-day bactericidal activity of meropenem, at different doses, with or without rifampin. Methods: Individuals with drug-sensitive pulmonary tuberculosis were randomized to one of four intravenous meropenem-based arms: 2 g every 8 hours (TID) (arm C), 2 g TID plus rifampin at 20 mg/kg once daily (arm D), 1 g TID (arm E), or 3 g once daily (arm F). All participants received amoxicillin/clavulanate with each meropenem dose. Serial overnight sputum samples were collected from baseline and throughout treatment. Median daily fall in colony-forming unit (CFU) counts per milliliter of sputum (solid culture) (EBACFU0–14) and increase in time to positive culture (TTP) in liquid media were estimated with mixed-effects modeling. Serial blood samples were collected for pharmacokinetic analysis on Day 13. Measurements and Main Results: Sixty participants enrolled. Median EBACFU0–14 counts (2.5th–97.5th percentiles) were 0.22 (0.12–0.33), 0.12 (0.057–0.21), 0.059 (0.033–0.097), and 0.053 (0.035–0.081); TTP increased by 0.34 (0.21–0.75), 0.11 (0.052–0.37), 0.094 (0.034–0.23), and 0.12 (0.04–0.41) (log10 h), for arms C–F, respectively. Meropenem pharmacokinetics were not affected by rifampin coadministration. Twelve participants withdrew early, many of whom cited gastrointestinal adverse events. Conclusions: Bactericidal activity was greater with the World Health Organization–recommended total daily dose of 6 g daily than with a lower dose of 3 g daily. This difference was only detectable with solid culture. Tolerability of intravenous meropenem, with amoxicillin/clavulanate, though, was poor at all doses, calling into question the utility of this drug in second-line regimens. Clinical trial registered with www.clinicaltrials.gov (NCT03174184).

1 December 2023 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
SJSaskia Janssen
Saskia Janssen
CUCaryn Megan Upton
Caryn Megan Upton
VJVeronique R. De Jager
Veronique R. De Jager
AFAlan Faraj
Alan Faraj
MPMadhurananda Pahar
Madhurananda Pahar
TNThomas R. Niesler
Thomas R. Niesler

23 June 2020 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
ADAndreas H. Diacon
Andreas H. Diacon
VJVeronique R. De Jager
Veronique R. De Jager
RDRodney Dawson
Rodney Dawson
KNKim Narunsky
Kim Narunsky
NVNaadira Vanker
Naadira Vanker
CMCarl M. Mendel
Carl M. Mendel
We thank Kim and colleagues for their interest in our study.…

21 January 2026 in medRxiv
Verified
Preprint
Open access
PDF file
MMMairi CW McClean
Mairi CW McClean
SKSimon E Koele
Simon E Koele
JDJulia Dreisbach
Julia Dreisbach
SMSusanne Mirold-Mei
Susanne Mirold-Mei
FNFred Njeleka
Fred Njeleka
MHMichael Hoelscher
Michael Hoelscher
Culture-based monitoring of bacterial load is slow and susceptible to missing data, contributing to the length and cost of TB clinical trials. Non-culture-based alternatives, like the Tuberculosis Molecular Load Bacterial Assay (TB-MBLA), could represent a solution. Our objectives were to evaluate TB-MBLA as a biomarker in early bactericidal activity (EBA) studies and explore whether combining biomarkers with joint modelling could provide insight into underlying biological processes and reduce data loss. We generated TB-MBLA (LifeArc (R) ) data from sputum samples from all 78 patients from the PanACEA BTZ-043 Phase Ib/IIa trial. In addition, we defined a joint biomarker as the first principal component derived from a probabilistic principal component analysis (pPCA) integrating TB-MBLA, colony forming units (CFU), and time-to-positivity (TTP) data. With TB-MBLA alone and the principal component 1 (PC1) marker we reevaluated the original stage IIa dose-response and stages Ib/IIa pharmacokinetics - pharmacodynamics (PK-PD) exposure-response analyses, applying linear and non-linear mixed models, respectively. For TB-MBLA, we could not detect an exposure-response effect in the PK-PD analysis, in contrast with CFU and TTP. When combining biomarkers, we observed a significant but less pronounced Emax exposure–response between days 0–3 compared with CFU and TTP alone. We also successfully applied pPCA as a modelling framework and show evidence that combining CFU and TTP in a joint latent component can improve detection of treatment effects compared with either biomarker alone. STUDY HIGHLIGHTS: What is the current knowledge on the topic?: BTZ-043 is a first-in-class antimycobacterial compound with promising applications in drug-sensitive pulmonary tuberculosis. TB EBA trials are typically conducted using sputum culture assays for dose-exposure-response modelling, but the technical challenges of these assays limit their effectiveness. What question did this study address?: How does the novel RT-qPCR assay TB-MBLA perform as a dose-exposure response marker for novel antitubercular compound BTZ-043 and what are the effects of joint modelling approaches in EBA modelling tasks? What does this study add to our knowledge?: We did not observe a significant exposure response for BTZ-043 in TB-MBLA over the 14-day treatment window. Joint modelling with pPCA can overcome the issues of missing and contaminated data that are canonical of culture data from TB treatment monitoring cohorts. How might this change drug discovery, development, and/or therapeutics?: Designing EBA trials should consider the drug-bacterial subpopulation axis of the specific study drug to maximise efficiency. Latent variable modelling techniques can be an effective and efficient framework for modelling Mycobacterial tuberculosis load in EBA trials.

17 December 2023 in BMJ Global Health
Verified
Conference Paper
Open access
PDF file
CUCaryn Megan Upton
Caryn Megan Upton
VJVeronique De Jager
Veronique De Jager
USUlrika Simonsson
Ulrika Simonsson
LMLaurynas Mockeliunas
Laurynas Mockeliunas
TMThabo Mabuka
Thabo Mabuka
ADAndreas Diacon
Andreas Diacon
Background Repurposing established antibiotics for TB has been successful, notably for fluoroquinolones, linezolid, and clofazimine. Meropenem co-administered with amoxicillin/clavulanate (A/Clav) demonstrated early bactericidal activity (EBA) in clinical trials (Diacon 2016; de Jager 2020; de Jager 2022). This study evaluated different regimens of carbapenems, A/Clav, and rifampicin, alone or in combinations. Methods This phase 2a, open-label, randomized trial recruited 132 HIV-negative adults with newly diagnosed, smear-positive, rifampicin-susceptible pulmonary TB. Participants received 14 days of treatment in one of 8 experimental arms, or standard-of-care (HRZE). EBA was determined with mixed effects modelling and reported as change in time (hours) to sputum culture positivity (TTP0-14) of samples collected overnight with 95% confidence intervals. Adverse events (AE) were assessed daily. Results A/Clav 2x1000/62.5mg orally twice daily showed no activity. TTP0-14 of other drugs in combination with A/Clav was, for meropenem 6g over 6 hours(6Mero6): 58.02 hours (18.72–192.92), meropenem 6g over 1 hour(6Mero1): 58.13 hours (27.26–121.83), meropenem 3g over 1 hour twice daily(3x2Mero): 60.07 hours (19.89–884.71), and meropenem 4g over 1 hour(4Mero1): 35.28 hours (25.31–84.74). Ertapenem 1g daily intravenously (ErtaIV) or intramuscularly (ErtaIM) was not active. The activity of rifampicin 35mg/kg daily plus A/Clav was 136.92 hours (103.21–400.64) and HRZE 134.30 hours (106.28–160.23). In 58 participants, 111 adverse events were reported. Most commonly diarrhoea (15 participants: four ErtaIM, three ErtaIV, four 6Mero6, two rifampicin, one each A/Clav and HRZE), injection site reactions (six participants: four ErtaIM, one each 6Mero6 and 3x2Mero), and raised transaminases (four participants: A/Clav, ErtaIM, Erta IV, rifampicin). Three SAEs occurred (pneumonia in ErtaIV, haemoptysis in rifampicin and 6Mero1) unrelated to treatment. Conclusion Rifampicin-based treatments showed the highest EBA. A/Clav and meropenem given at 6g per day, in single or divided doses, had higher EBA than lower doses, and shorter infusions were better tolerated. Ertapenem-based treatments and A/Clav alone showed no anti-TB activity. Funding: EDCTP 733079-H2020-SC1-2016-RTD